Juvenile Idiopathic Arthritis (JIA) research hub
4 indexed studies · 3 currently recruiting
- recruitingPhase II and Phase III (Integrated)
A3921145 - A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
This study is looking at the long-term safety and effects of a medicine called tofacitinib for treating juvenile idiopathic arthritis (JIA) in young people. Researchers will check things like growth, overall health, and how well the medicine controls their JIA.
Spain · Belgium · Poland - active not recruitingPHASE1
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
This study looks at a new medicine called Upadacitinib for children aged 2-17 with a type of arthritis called Juvenile Idiopathic Arthritis (JIA). We're checking how the medicine works in their bodies, if it's safe, and if they can tolerate it.
United States · Canada · Germany - recruiting
CAPRI National Juvenile Idiopathic Arthritis Registry
This study tracks Canadian children with Juvenile Idiopathic Arthritis (JIA) to better understand the condition and how treatments work. It helps doctors learn more about JIA's long-term effects and improve care for children living with it.
Canada - recruitingPHASE3
OLE Study With Filgotinib in JIA
This study looks at the long-term safety and effects of a medicine called filgotinib in children and young people with arthritis. It's for those who have already seen good results from filgotinib in previous studies.
France · Germany · United Kingdom